Celcuity (CELC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
The annual meeting is scheduled for May 14, 2026, to vote on director elections, auditor ratification, executive compensation, a new stock incentive plan, and an amended employee stock purchase plan.
Shareholders of record as of March 17, 2026, are entitled to vote, with 48,336,675 shares outstanding.
Proxy materials are available online, and voting can be done by mail, phone, or internet.
Voting matters and shareholder proposals
Proposals include electing eight directors, ratifying Boulay PLLP as auditor, approving executive compensation (say-on-pay), adopting the 2026 Stock Incentive Plan, and amending the 2017 Employee Stock Purchase Plan.
The board recommends voting FOR all proposals.
Shareholder proposals and director nominations for the 2027 meeting must comply with advance notice bylaws.
Board of directors and corporate governance
The board consists of eight nominees, with a majority qualifying as independent under Nasdaq rules.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The board has adopted codes of ethics, an anti-bribery policy, and a policy prohibiting insider trading and hedging.
Family relationships exist between two executive officers (brother-in-law relationship).
Latest events from Celcuity
- Key votes include director elections, auditor ratification, and approval of equity plans.CELC
Proxy filing2 Apr 2026 - FDA Priority Review, strong trial data, and $441.5M cash position support 2026 launch.CELC
Q4 202525 Mar 2026 - Gedatolisib demonstrates leading efficacy in breast cancer, with launch and global expansion underway.CELC
Leerink Global Healthcare Conference 202610 Mar 2026 - Gedatolisib nears launch with strong trial data, regulatory momentum, and $10B+ peak potential.CELC
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Gedatolisib nears approval with strong efficacy, broad utility, and major commercial potential.CELC
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026 - Phase III breast cancer trial for gedatolisib on track, with strong safety and multi-billion market potential.CELC
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q2 saw robust clinical progress, $129M raised, and $283.1M cash reserves for future growth.CELC
Q2 20241 Feb 2026 - Gedatolisib set new benchmarks in efficacy and safety for advanced breast cancer.CELC
Status Update14 Jan 2026 - Phase III enrollment milestones reached; $264M cash supports pivotal 2025 data and operations.CELC
Q3 202413 Jan 2026